2. Academic Validation
  3. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression

  • Br J Cancer. 2018 Jan;118(2):213-223. doi: 10.1038/bjc.2017.393.
Eiji Kashiwagi 1 2,  Satoshi Inoue 1 2 3 4,  Taichi Mizushima 1 2 3 4,  Jinbo Chen 3 4,  Hiroki Ide 1 2,  Takashi Kawahara 1 2 3,  Leonardo O Reis 1 2,  Alexander S Baras 1 2,  George J Netto 1 2,  Hiroshi Miyamoto 1 2 3 4 5
Affiliations

Affiliations

  • 1 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • 2 James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • 3 Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
  • 4 James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.
  • 5 Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA.
PMID: 29123257 DOI: 10.1038/bjc.2017.393
Abstract

Background: We investigated the role of prostaglandin receptors (e.g. prostaglandin E2 receptor 2 (EP2), EP4) and the efficacy of celecoxib in urothelial tumourigenesis and Cancer progression.

Methods: We performed immunohistochemistry in bladder Cancer (BC) tissue microarrays, in vitro transformation assay in a normal urothelial SVHUC line, and western blot/reverse transcription-polymerase chain reaction/cell growth assays in BC lines.

Results: EP2/EP4 expression was elevated in BCs compared with non-neoplastic urothelial tissues and in BCs from those who were resistant to cisplatin-based neoadjuvant chemotherapy. Strong positivity of EP2/EP4 in non-muscle-invasive tumours or positivity of EP2/EP4 in muscle-invasive tumours strongly correlated with disease progression or disease-specific mortality, respectively. In SVHUC cells, exposure to a chemical carcinogen 3-methylcholanthrene considerably increased and decreased the expression of EP2/EP4 and Phosphatase and tensin homologue (PTEN), respectively. Treatment with selective EP2/EP4 antagonist or celecoxib also resulted in prevention in 3-methylcholanthrene-induced neoplastic transformation of SVHUC cells. In BC lines, EP2/EP4 antagonists and celecoxib effectively inhibited cell viability and migration, as well as augmented PTEN expression. Furthermore, these drugs enhanced the cytotoxic activity of cisplatin in BC cells. EP2/EP4 and PTEN were also elevated and reduced, respectively, in cisplatin-resistant BC sublines.

Conclusions: EP2/EP4 activation correlates with induction of urothelial Cancer initiation and outgrowth, as well as chemoresistance, presumably via downregulating PTEN expression.

Figures
Products